5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Syncom Formulations (India) Ltd.

•
sfil.inBSE: 524470NSE: SYNCOMF
Market Cap₹ 1,817 Cr.
Current Price
High / Low₹ 23 / 10
Stock P/E21.4
Book Value₹ 5
Price to Book4.55
Dividend Yield0.00 %
ROCE18.7 %
ROE15.6 %
Face Value₹ 1

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2025 • Pharmacutical Drugs & Formulations: 97.5% • Trading of Comodities: 1.7% • Renting of Property: 0.8%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has delivered good profit growth of 27.9% CAGR over last 5 years
  • Company is almost debt free
  • Latest quarter profit grew 56.3% YoY, showing strong momentum
  • Company has delivered good sales growth of 17.6% CAGR over last 5 years
  • Company comfortably covers its interest (77.1x coverage)
  • Working capital cycle has improved - days down from 237 to 165

CONS

  • A large part of profit comes from other income (26.6% of PBT)
  • Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.30x)
  • Recurring exceptional / one-off items are inflating headline profit
  • Operating margins have contracted to 11.6% from 14.6%

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1864.0036.98447236.040.862901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9405.0085.36249673.200.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4928.4085.95187460.490.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1118.0024.71111520.930.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1380.0033.08111484.470.94785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1936.0095.67104604.450.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1669.0025.8796030.570.241032.0325.229150.3517.4412.7620.54
8.DRREDDY1140.8029.5595220.280.70435.60-69.108099.80-5.2113.7510.63
9.LUPIN2075.0017.1694882.670.871416.9816.018276.8934.2828.8629.59
10.MANKIND2246.0045.4292769.930.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2417.0037.9468213.700.10482.83927.884018.4831.3520.3520.03
12.SYNCOMF19.3321.241817.020.0024.8557.72125.537.3818.7720.88
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
5962637387101127148117121115134125
53565764769011213110110393113101
Operating Profit6679101215171619212124
OPM %10.36%9.76%10.74%12.02%12.06%11.75%11.49%11.77%13.54%15.42%18.47%16.04%19.33%
24431447655148
Interest1111000000000
Depreciation1111111111122
Profit before Tax6899101517232022253332
Tax %27.02%23.83%25.35%26.71%24.46%25.26%24.32%23.95%22.36%24.69%24.71%25.23%22.94%
Net Profit466781113181617192525
0.070.080.090.090.110.160.140.190.210.180.230.260.26

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
184185159187206245220225258463495
167168147175189207200205231409409
Operating Profit1716121217382020285485
OPM %9.06%8.88%7.38%6.34%8.17%15.54%9.12%8.85%10.78%11.56%17.28%
3345571215131733
Interest00001023411
Depreciation33444445557
Profit before Tax16161213174126273265112
Tax %35.68%33.41%28.03%12.51%17.56%28.33%24.39%24.45%25.62%24.42%24.35%
Net Profit101191114292020244985
EPS0.130.130.120.140.170.370.240.240.250.52—
Dividend Payout %15.07%14.66%0.00%0.00%0.00%0.00%13.07%0.00%0.00%0.00%—

COMPOUNDED SALES GROWTH

10 Years:
10%
5 Years:
18%
3 Years:
28%

COMPOUNDED PROFIT GROWTH

10 Years:
17%
5 Years:
28%
3 Years:
35%

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
33%
1 Year:
8%

RETURN ON EQUITY

10 Years:
11%
5 Years:
12%
3 Years:
11%
Last Year:
16%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Sep 23

₹ 0.10

Rs.0.1000 per share(10%)Final Dividend

2022

Sep 9

₹ 0.03

Rs.0.0300 per share(3%)Final Dividend

2017

Sep 21

₹ 0.02

Rs.0.0200 per share(2%)Dividend

2016

Sep 22

₹ 0.02

Rs.0.0200 per share(2%)Dividend

2015

Sep 16

₹ 0.02

Rs.0.0200 per share(2%)Dividend

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital78787878787986949494
313644556899131162192246
61314104645985735
Trade Payables47322221202914201443
19191612142118162024
Total Liabilities181179174176184292308377394412
46555848464447437278
Capital Work in Progress50100062600
2312211143646693
15101114162320212141
0000000093107
Cash & Bank676896409681
85105961051131491922147393
Total Assets181179174176184292308377394412

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
3021181092317-623
Cash from Investing-23-8-222-75-27-4584-18
Cash from Financing-2-2-2-0-772835-15-68
-16-671-5-2163-63

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
50.5750.5750.5750.5750.5750.5750.5750.5750.57
0.090.100.130.110.410.100.260.210.35
DIIs0.000.000.000.000.000.000.000.000.00
Government0.000.000.000.000.000.000.000.000.00
49.3449.3349.3049.3249.0249.3349.1749.2149.08

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-08
Copy of Newspaper Publication

2026-09-08 - Syncom Formulations (India) Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-07
General Updates

2026-09-07 - Syncom Formulations (India) Limited has informed the Exchange about General Updates

2026-09-07
General Updates

2026-09-07 - Syncom Formulations (India) Limited has informed the Exchange about General Updates

2026-09-07
Shareholders meeting

2026-09-07 - Syncom Formulations (India) Limited has informed the Exchange about Shareholders meeting

2026-09-01
Copy of Newspaper Publication

2026-09-01 - Syncom Formulations (India) Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-13
General Updates

2026-08-13 - Syncom Formulations (India) Limited has informed the Exchange about General Updates

2026-08-13
Disclosure of material issue

2026-08-13 - Syncom Formulations (India) Limited has informed regarding Disclosure of material issue

2026-08-13
Disclosure of material issue

2026-08-13 - Syncom Formulations (India) Limited has informed regarding Disclosure of material issue

2026-08-12
Copy of Newspaper Publication

2026-08-12 - Syncom Formulations (India) Limited has informed the Exchange about Copy of Newspaper Publication

News

Recent coverage and analyst commentary for SYNCOMF

Loading news…

🤖

AI Stock Analyst

Syncom Formulations (India) Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login